Portal de Periódicos da CAPES

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial

2023; Lippincott Williams & Wilkins; Volume: 147; Issue: 22 Linguagem: Inglês

10.1161/circulationaha.122.062021

1524-4539

Moritz Hundertmark, Amanda Adler, Charalambos Antoniades, Ruth L. Coleman, Julian L. Griffin, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J. Miller, Joanne Milton, Shveta Monga, Ferenc Mózes, Areesha Nazeer, Betty Raman, Oliver J. Rider, Christopher T. Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer,

Heart Failure Treatment and Management

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness.